Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Long noncoding RNA expression profile of chemotherapy-sensitive and resistant breast cancer tissues

ABSTRACT: Long noncoding RNA expression profile of chemotherapy-sensitive and resistant breast cancer tissues

PROVIDER: PRJNA912687 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Long noncoding RNA expression profile of chemotherapy-sensitive and resistant breast cancer tissues

Project description:To explore novel lncRNAs relative to chemo-resistance in breast cancer, we performed lncRNA microarray analysis using three anthracycline-resistant tissues and three anthracycline-sensitive tissues collected before neoadjuvant chemotherapy by Arraystar Human LncRNA Microarray V3.0.

2024-07-16 | GSE221060 | GEO

Long noncoding RNA expression profile of breast cancer tissues pre- and post-neoadjuvant chemotherapy

Project description:Long noncoding RNA expression profile of breast cancer tissues pre- and post-neoadjuvant chemotherapy

| PRJNA912689 | ENA

Long noncoding RNA expression profile of breast cancer tissues pre- and post-neoadjuvant chemotherapy

Project description:To identify the differential expression of lncRNAs, we performed the lncRNA microarray analysis with three pairs of breast cancer tissues before and after neoadjuvant chemotherapy (NAC) from partially responded patients by Arraystar Human LncRNA Microarray V3.0.

2024-07-16 | GSE221061 | GEO

Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients

Project description:1. Evaluate the diagnostic value of long noncoding RNA (CCAT1) expression by RT-PCR in peripheral blood in colorectal cancer patients versus normal healthy control personal. 2. Evaluate the clinical utility of detecting long noncoding RNA (CCAT1) expression in diagnosis of colorectal cancer patients & its relation to tumor staging. 3. Evaluate the clinical utility of detecting long noncoding RNA (CCAT1) expression in precancerous colorectal diseases. 4. Compare long noncoding RNA (CCAT1) expression with traditional marker; carcinoembryonic antigen (CEA) and Carbohydrate antigen 19-9 (CA19-9) in diagnosis of colorectal cancer.

| 2330122 | ecrin-mdr-crc

Long noncoding RNA expression in rituximab-sensitive and -resistant diffuse large B-cell lymphoma cell lines

Project description:Diffuse large B-cell lymphoma is an aggressive tumor, killing approximately 200,000 people each year. Rituximab, a recombinant monoclonal CD20 antibody, added to the treatment scheme in 1997 improved both progression-free survival and general survival rate. Despite the existing treatment and relatively high cure rate, 30-40% of the patients develop a relapse or are originally resistant. Long noncoding RNAs (lncRNAs) have been implicated as regulators of numerous important cancer-related processes, including establishment and maintenance of anti-cancer drug resistance. However, their role in DLBCL resistance to the treatment is poorly understood. In this study, we analyzed gene expression in DLBCL cell lines, either sensitive or resistant to rituximab.

2021-01-03 | GSE159852 | GEO

Identification of differentially expressed miRNAs in drug resistant and drug sensitive breast cancer tissues

Project description:To identify miRNAs involved in drug resistance of human breast cancer, a miRNA microarray was performed on 5 cases of drug resistant tissues and 5 cases of drug sensitive tissues.The expression levels of totally 2019 miRNAs in 5 pairs of matched, drug resistant and drug sensitive tissues were examined by microarray. There were 27 differentially expressed miRNAs between drug resistant and drug sensitive tissues were identified of which there were 11 significantly up-regulated while the other 16 were down-regulated in drug resistant tissues compared to drug sensitive tissues. It was found that miR-489 was one of the most downregulated miRNAs in drug resistant tissues.

2017-08-01 | GSE71142 | GEO

Transcriptomic analysis of breast cancer patients sensitive and resistant to chemotherapy: Looking for overall survival and drug resistance biomarkers

Project description:Purpose: Neoadjuvant chemotherapy is one important therapeutic strategy for breast cancer with the drawback of resistance development. Chemotherapy has adverse effects that combined with resistance could contribute to lower overall survival. This work aimed to evaluate the molecular profile of patients who received neoadjuvant chemotherapy trying to discover differentially expressed genes (DEGs) that could be used as biomarkers of chemotherapy response and overall survival. Methods: Breast cancer patients who received neoadjuvant chemotherapy were enrolled in this study and according to their pathological response were assigned as sensitive or resistant. To evaluate DEGs, GO, KEGG and protein-protein interactions, RNAseq information from all patients was obtained by next generation sequencing. Results: A total of 1985 DEGs were found and KEGG analysis indicated a great number of DEGs in metabolic pathways, pathways in cancer, cytokine-cytokine receptor interactions, and neuroactive ligand-receptor interactions. A selection of 73 DEGs were used further for an analysis of overall survival using the METABRIC study. Seven of those DEGs were found to correlated with overall survival, of them the sub-expression of C1QTNF3, CTF1, OLFML3, PLA2R1, PODN and the over expression of TUBB and TCP1 were found in resistant patients and related to patients with lower overall survival. Conclusions: This work highlights differences at the level of gene expression in patients resistant and sensitive to neoadjuvant chemotherapy. Cellular components related to extracellular region and plasma membrane were mainly involved. Furthermore, 73 DEGs were able to discriminate patients resistant and sensitive to neoadjuvant chemotherapy, and 7 of them were able to predict overall survival.

2021-04-30 | GSE162187 | GEO

RNA-Seq of neuroblastoma Th-MYCN mouse model, samples sensitive to chemotherapy, and those with chemotherapy resistance

Project description:Some neuroblastoma patients relapse after chemotherapy. Here, a Th-MYCNCPM32 mouse model usually have spontaneously tumours which are sensitive to chemotherapy. By treating mice with consecutive cycles of sublethal cyclophosphamide (CPM) using a personal dose escalation protocol (PDE), resistant tumours may develop. This experiment aims to compare the expression profiles (RNA-Seq) of sensitive and resistant MYCN driven tumours in order to understand the mechanisms behind resistance. Samples also presented cross-resistance to vincristine and doxorubicin.

2018-09-30 | E-MTAB-5858 | biostudies-arrayexpress

Long noncoding RNA (lncRNA) expression profiles in colorectal cancer tissues and paired adjacent normal tissues

Project description:Long noncoding RNAs (lncRNAs) play important roles in the tumorigenesis and metastasis of colorectal cancer (CRC). This study used a lncRNA microarray to analyze the aberrant lncRNA expression profiles in CRC tissues compared with paired adjacent normal tissues as well as CRC with regional lymph nodes metastasis compared with CRC without regional lymph nodes metastasis.

2020-05-12 | GSE84983 | GEO

Long noncoding RNA expression in rituximab-sensitive and -resistant diffuse large B-cell lymphoma cell lines

Project description:Long noncoding RNA expression in rituximab-sensitive and -resistant diffuse large B-cell lymphoma cell lines

| PRJNA670697 | ENA